HRP20161260T1 - Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže - Google Patents
Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže Download PDFInfo
- Publication number
- HRP20161260T1 HRP20161260T1 HRP20161260TT HRP20161260T HRP20161260T1 HR P20161260 T1 HRP20161260 T1 HR P20161260T1 HR P20161260T T HRP20161260T T HR P20161260TT HR P20161260 T HRP20161260 T HR P20161260T HR P20161260 T1 HRP20161260 T1 HR P20161260T1
- Authority
- HR
- Croatia
- Prior art keywords
- ethyl
- phenyl
- benzoylphenyl
- amino
- methyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- -1 2-thiophenyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 241000689227 Cora <basidiomycete fungus> Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- NXYBJQHVLSKAPY-CYBMUJFWSA-N 5-[[(1r)-1-(3-benzoylphenyl)ethyl]sulfamoyl]furan-2-carboxylic acid Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(=O)C=1C=CC=CC=1)S(=O)(=O)C1=CC=C(C(O)=O)O1 NXYBJQHVLSKAPY-CYBMUJFWSA-N 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 210000003622 mature neutrocyte Anatomy 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- ZMYOUFPHQJKELU-CQSZACIVSA-N methyl 5-[[(1r)-1-(3-benzoylphenyl)ethyl]sulfamoyl]furan-2-carboxylate Chemical compound O1C(C(=O)OC)=CC=C1S(=O)(=O)N[C@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ZMYOUFPHQJKELU-CQSZACIVSA-N 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- FGLNWUFALWTUAQ-GOSISDBHSA-N n-[(1r)-1-(3-benzoylphenyl)ethyl]-3-pyrrolidin-1-ylpropane-1-sulfonamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(=O)C=1C=CC=CC=1)S(=O)(=O)CCCN1CCCC1 FGLNWUFALWTUAQ-GOSISDBHSA-N 0.000 claims 1
- UMSKMMCPIQKZRN-MRXNPFEDSA-N n-[(1r)-1-(3-benzoylphenyl)ethyl]benzamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(=O)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 UMSKMMCPIQKZRN-MRXNPFEDSA-N 0.000 claims 1
- FWYCISGSELVIOA-MRXNPFEDSA-N n-[(1r)-1-(3-benzoylphenyl)ethyl]benzenesulfonamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(=O)C=1C=CC=CC=1)S(=O)(=O)C1=CC=CC=C1 FWYCISGSELVIOA-MRXNPFEDSA-N 0.000 claims 1
- ZEVFLVXOLQXIAV-CQSZACIVSA-N n-[(1r)-1-(3-benzoylphenyl)ethyl]cyclobutanecarboxamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(=O)C=1C=CC=CC=1)C(=O)C1CCC1 ZEVFLVXOLQXIAV-CQSZACIVSA-N 0.000 claims 1
- ZWKAOTTVIALVGU-GFCCVEGCSA-N n-[(1r)-1-(3-benzoylphenyl)ethyl]methanesulfonamide Chemical compound CS(=O)(=O)N[C@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 ZWKAOTTVIALVGU-GFCCVEGCSA-N 0.000 claims 1
- ZZJNFTIRZLFKLR-CQSZACIVSA-N n-[(1r)-1-(3-benzoylphenyl)ethyl]thiophene-2-sulfonamide Chemical compound N([C@H](C)C=1C=C(C=CC=1)C(=O)C=1C=CC=CC=1)S(=O)(=O)C1=CC=CS1 ZZJNFTIRZLFKLR-CQSZACIVSA-N 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- GRJHONXDTNBDTC-UHFFFAOYSA-N phenyl trifluoromethanesulfonate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=CC=C1 GRJHONXDTNBDTC-UHFFFAOYSA-N 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/76—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
- C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Claims (7)
1. (R)-Arilalkilamino derivati formule (I):
[image]
u kojoj R je
- 2-tiazolil, nesupstituiran ili supstituiran sa grupom izabranom od metila ili trifluorometila;
- CORa, SO2Ra
gdje
Ra je izabran od:
- C1-C5-alkil, C3-C5-cikloalkil;
- fenil, 2-piridil, 2-furil, 2-tiofenil grupa;
- grupe formule II,
[image]
gdje
X predstavlja:
linearni ili razgranati C1-C6 alkilen,
R2 i R3 zajedno sa N atomom za koji su vezani, formiraju 4-6 –člani heterociklični prsten koji sadrži dušik formule (III)
[image]
gdje Y predstavlja CH2, i p predstavlja cijeli broj od 0 do 2;
R1 je metil;
Ar je izabran od:
3’ -benzoilfenila, 3’ -(4-kloro-benzoil)-fenila, 3 ’ -(4-metil-benzoil)-fenila,
4’-trifluorometansulfoniloksi-fenila, 4’-benzensulfoniloksi-fenila, 3’-(furan-2-karbonil)-fenila.
2. Spoj izabran od:
4-{(1R)-1-[(fenilsulfonil)amino]etil}fenil trifluorometansulfonata
N-[(1R)-1-(3-benzoilfenil)etil]benzensulfonamida
4-{(1R)-1-[(piridin-3-ilsulfonil)amino]etil}feniltrifluorometansulfonata
N-[(1R)-1-(3-benzoilfenil)etil]metansulfonamida
N-{(1R)-1-[3-(2-furoil)fenil]etil}tiofen-2-sulfonamida
N-{(1R)-1-[3-(2-furoil)fenil]etil}metansulfonamida
4-{(1R)-1-[(tien-2-ilsulfonil)amino]etil}fenil trifluorometansulfonata
N-[(1R)-1-(3-benzoilfenil)etil]tiofen-2-sulfonamida
N-[(1R)-1-(3-benzoilfenil)etil]-3-pirolidin-1-ilpropan-1-sulfonamida
metil 5-({[(1R)-1-(3-benzoilfenil)etil]amino}sulfonil)-2-furoata
5-({[(1R)-1-(3-benzoilfenil)etil]amino}sulfonil)-2-furoinske kiseline
4-{(1R)-2-metil-1-[(metilsulfonil)amino]propil}feniltrifluorometansulfonata
N-((1R)-1-{4-[1-metil-1-(fenilsulfonil)etil]fenil}etil)metansulfonamida
4-[(1R)-1-(izobutirilamino)etil]feniltrifluorometansulfonata
4-{[(1R)-1-(piridin-3-ilkarbonil)amino]etil]}feniltrifluorometansulfonata
N-[(1R)-1-(3-benzoilfenil)etil]benzamida
N-[(1R)-1-(3-benzoilfenil)etil]-2-furamida
N-[(1R)-1-(3-benzoilfenil)etil]ciklobutankarboksamida
N-[(1R)-1-(4-trifluorometansulfoniloksi)feniletil]-4-piperidin-1-ilbutanamida
4-{(1R)-1-[(4-pirolidin-1-ilbutanoil)amino]etil]}fenil trifluorometansulfonata
3-{(1R)-1-[4-(4-trifluorometil-1,3-tiazol-2-il)amino]etil}fenil) (fenil)metanona.
3. Spojevi prema patentnom zahtjevu 1 ili 2, za uporabu kao lijekovi.
4. Spojevi prema patentnom zahtjevu 1 ili 2, za uporabu kao lijek za liječenje bolesti koje uključuju kemotaksiju humanih PMN induciranu sa C5a.
5. Spojevi za uporabu prema patentnom zahtjevu 4 naznačeni time što navedene bolesti su: sepsa, psorijaza, bulozni pemfigoid, reumatoidni artritis, ulcerozni kolitis, akutni respiratorni distres sindrom, idiopatska fibroza, cistična fibroza, kronična opstruktivna bolest pluća, glomerulonefritis i u prevenciji i liječenju povrede uzrokovane ishemijom i reperfuzijom.
6. Postupak za pripremu spojeva formule (I)
[image]
gdje R je CORa ili SO2Ra i Ra je kao što je definiran u patentnom zahtjevu 1, koji sadrži reakciju između (R)-arilalkilamina formule (IV)
[image]
gdje Ar i R1 su kao što su definirani u patentnom zahtjevu 1, sa odgovarajućim acil ili sulfonil kloridima.
7. Farmaceutski pripravci koji sadrže spoj prema patentnom zahtjevu 1 ili 2 u smjesi sa njihovim pogodnim nosačem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05111257 | 2005-11-24 | ||
| PCT/EP2006/068867 WO2007060215A2 (en) | 2005-11-24 | 2006-11-24 | (r)-arylkylamino derivatives and pharmaceutical compositions containing them |
| EP06819736.7A EP1951663B1 (en) | 2005-11-24 | 2006-11-24 | (r)-arylkylamino derivatives and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161260T1 true HRP20161260T1 (hr) | 2016-11-18 |
Family
ID=37865701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161260TT HRP20161260T1 (hr) | 2005-11-24 | 2016-10-03 | Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8026367B2 (hr) |
| EP (1) | EP1951663B1 (hr) |
| JP (2) | JP5374157B2 (hr) |
| CN (1) | CN101360706B (hr) |
| AU (1) | AU2006316452B2 (hr) |
| CA (1) | CA2629935C (hr) |
| CY (1) | CY1118109T1 (hr) |
| DK (1) | DK1951663T3 (hr) |
| ES (1) | ES2597843T3 (hr) |
| HK (1) | HK1127592A1 (hr) |
| HR (1) | HRP20161260T1 (hr) |
| HU (1) | HUE031466T2 (hr) |
| LT (1) | LT1951663T (hr) |
| PL (1) | PL1951663T3 (hr) |
| PT (1) | PT1951663T (hr) |
| RS (1) | RS55192B1 (hr) |
| RU (1) | RU2458051C2 (hr) |
| SI (1) | SI1951663T1 (hr) |
| WO (1) | WO2007060215A2 (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8793748B2 (en) * | 2007-07-26 | 2014-07-29 | The Directv Group, Inc. | Method and system for controlling communication between a user device and a content delivery network |
| US20090028317A1 (en) * | 2007-07-26 | 2009-01-29 | The Directv Group, Inc. | Method and system for providing callbacks from a user device using an ip network |
| PT2201006E (pt) * | 2007-10-18 | 2011-05-05 | Domp S P A | Derivados de (r)-4-(heteroaril)-feniletilo e composi??es farmac?uticas que os cont?m |
| CA2965223C (en) | 2008-12-22 | 2019-09-24 | Chemocentryx, Inc. | C5ar antagonists |
| JP2013529647A (ja) | 2010-06-24 | 2013-07-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａＲアンタゴニスト |
| TW201329025A (zh) | 2011-11-01 | 2013-07-16 | Astex Therapeutics Ltd | 醫藥化合物 |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| CN104623687B (zh) * | 2015-03-11 | 2017-09-05 | 中国科学院上海高等研究院 | 利用美登醇制备的抗体药物偶联物及其制备方法和应用 |
| WO2017123716A1 (en) | 2016-01-14 | 2017-07-20 | Chemocentryx, Inc. | Method of treating c3 glomerulopathy |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
| TW202012396A (zh) * | 2018-04-18 | 2020-04-01 | 美商德洛斯股份有限公司 | 具乙烯磺醯胺部分之k-ras調節劑 |
| EP4059497A1 (en) | 2021-03-17 | 2022-09-21 | Dompé farmaceutici S.p.a. | C5ar1 inhibitors for treating hypersensitivity reactions to taxanes |
| IL305727A (en) | 2021-03-17 | 2023-11-01 | Dompe Farm Spa | C5AR1 inhibitors to treat a hypersensitivity reaction to TAXANES |
| EP4397306A1 (en) | 2023-01-05 | 2024-07-10 | Dompe' Farmaceutici S.P.A. | C5ar1 inhibitors for use in the treatment of ocular mucous membrane pemphigoid and/or oral mucous membrane pemphigoid |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62252755A (ja) * | 1986-04-11 | 1987-11-04 | Daikin Ind Ltd | 新規ｎ−ベンジルベンズアミド誘導体およびこれを有効成分として含有する除草剤 |
| US4861891A (en) * | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
| JPH09301933A (ja) * | 1996-05-14 | 1997-11-25 | Sumika Fine Chem Kk | アミン類の製造方法 |
| US6020335A (en) * | 1997-02-06 | 2000-02-01 | Pfizer Inc | (N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents |
| ATE293603T1 (de) * | 1997-10-14 | 2005-05-15 | Mitsubishi Pharma Corp | Piperazin-verbindungen und ihre medizinische verwendung |
| KR100565362B1 (ko) | 1997-10-27 | 2006-03-30 | 도야마 가가쿠 고교 가부시키가이샤 | 7-이소인돌린-퀴놀론 카복실산 유도체 및 그 중간체의 제조방법 및 7-이소인돌린-퀴놀론 카복실산 유도체의 염, 그의 수화물 및 이들을 활성성분으로 함유하는 조성물 |
| CN1294574A (zh) * | 1997-12-15 | 2001-05-09 | 阿肯色大学评议会 | 杀真菌酰胺 |
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| JP2003523942A (ja) * | 1999-06-30 | 2003-08-12 | メルク エンド カムパニー インコーポレーテッド | Ｓｒｃキナーゼ阻害剤化合物 |
| EP1326835A1 (en) * | 2000-10-05 | 2003-07-16 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide compounds as apo b secretion inhibitors |
| ITMI20010395A1 (it) * | 2001-02-27 | 2002-08-27 | Dompe Spa | Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate |
| CZ20032831A3 (cs) * | 2001-04-16 | 2004-03-17 | Schering Corporation | 3,4-Disubstituované cyklobuten-1,2-diony |
| MXPA04003439A (es) * | 2001-10-12 | 2004-07-08 | Schering Corp | Compuestos de maleimida 3,4 disustituidos como antagonistas de receptor de quimiocina cxc. |
| AU2003900587A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| US20050222408A1 (en) * | 2003-07-14 | 2005-10-06 | University Of Tennessee Research Foundation | Heterocyclic amides with anti-tuberculosis activity |
| BRPI0413324A (pt) * | 2003-08-06 | 2006-10-10 | Senomyx Inc | receptores de paladar hetero-oligoméricos t1r, linhas de células que expressam os ditos receptores, e compostos de paladar |
| JP4851943B2 (ja) * | 2003-12-22 | 2012-01-11 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドおよびｃｃ−ケモカインレセプターリガンドとしてのイソチアゾールジオキシド |
| GT200500013A (es) * | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
| CN101912382B (zh) * | 2004-03-23 | 2012-11-21 | 冬姆佩股份公司 | 2-苯基丙酸衍生物及含有它们的药物组合物 |
-
2006
- 2006-11-24 RU RU2008125433/04A patent/RU2458051C2/ru active
- 2006-11-24 RS RS20160819A patent/RS55192B1/sr unknown
- 2006-11-24 WO PCT/EP2006/068867 patent/WO2007060215A2/en active Application Filing
- 2006-11-24 LT LTEP06819736.7T patent/LT1951663T/lt unknown
- 2006-11-24 ES ES06819736.7T patent/ES2597843T3/es active Active
- 2006-11-24 AU AU2006316452A patent/AU2006316452B2/en active Active
- 2006-11-24 DK DK06819736.7T patent/DK1951663T3/en active
- 2006-11-24 CN CN2006800515567A patent/CN101360706B/zh active Active
- 2006-11-24 PT PT68197367T patent/PT1951663T/pt unknown
- 2006-11-24 HU HUE06819736A patent/HUE031466T2/hu unknown
- 2006-11-24 PL PL06819736T patent/PL1951663T3/pl unknown
- 2006-11-24 EP EP06819736.7A patent/EP1951663B1/en active Active
- 2006-11-24 SI SI200632098A patent/SI1951663T1/sl unknown
- 2006-11-24 JP JP2008541751A patent/JP5374157B2/ja active Active
- 2006-11-24 CA CA2629935A patent/CA2629935C/en active Active
- 2006-11-24 US US12/094,837 patent/US8026367B2/en active Active
-
2009
- 2009-07-22 HK HK09106699.2A patent/HK1127592A1/xx unknown
-
2013
- 2013-03-05 JP JP2013043160A patent/JP5730343B2/ja active Active
-
2016
- 2016-10-03 HR HRP20161260TT patent/HRP20161260T1/hr unknown
- 2016-10-18 CY CY20161101039T patent/CY1118109T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2008125433A (ru) | 2009-12-27 |
| CA2629935C (en) | 2016-01-19 |
| CY1118109T1 (el) | 2017-06-28 |
| EP1951663B1 (en) | 2016-07-20 |
| WO2007060215A3 (en) | 2007-10-04 |
| RS55192B1 (sr) | 2017-01-31 |
| ES2597843T3 (es) | 2017-01-23 |
| JP5374157B2 (ja) | 2013-12-25 |
| AU2006316452B2 (en) | 2013-01-10 |
| CN101360706B (zh) | 2013-10-02 |
| PT1951663T (pt) | 2016-10-03 |
| JP5730343B2 (ja) | 2015-06-10 |
| CA2629935A1 (en) | 2007-05-31 |
| SI1951663T1 (sl) | 2016-10-28 |
| WO2007060215A2 (en) | 2007-05-31 |
| PL1951663T3 (pl) | 2017-01-31 |
| LT1951663T (lt) | 2016-11-10 |
| DK1951663T3 (en) | 2016-10-10 |
| AU2006316452A1 (en) | 2007-05-31 |
| CN101360706A (zh) | 2009-02-04 |
| JP2013173743A (ja) | 2013-09-05 |
| EP1951663A2 (en) | 2008-08-06 |
| HK1127592A1 (en) | 2009-10-02 |
| HUE031466T2 (hu) | 2017-07-28 |
| JP2009517368A (ja) | 2009-04-30 |
| US20090124664A1 (en) | 2009-05-14 |
| RU2458051C2 (ru) | 2012-08-10 |
| US8026367B2 (en) | 2011-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161260T1 (hr) | Derivati (r)-arilkilamina i farmaceutski pripravci koji ih sadrže | |
| JP2009517368A5 (hr) | ||
| US7053234B2 (en) | Antibacterial agents | |
| ES2232914T3 (es) | Derivados de sulfonamida. | |
| JP5555169B2 (ja) | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド | |
| HRP20090681T1 (hr) | Derivati 2-fenilpropionske kiseline i farmaceutski pripravci koji ih sadrže | |
| JP5043645B2 (ja) | カルボン酸 | |
| RU2007128949A (ru) | Конденсированные бициклические карбоксамидные производные, используемые в качестве ингибиторов схсr2 для лечения воспалений | |
| JP2004523534A5 (hr) | ||
| JP2010501587A5 (hr) | ||
| RU2014121394A (ru) | Двузамещенные соединения диамино-3,4-циклобутен-3-диона-1,2, приемлемые для лечения паталогий, опосредованных хемокинами | |
| HRP20120577T1 (hr) | 3,4-diarilpirazoli kao inhibitori proteinskih kinaza | |
| RU2004100839A (ru) | Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов | |
| HUT77313A (hu) | Amidino-naftil-származékok és sóik, e vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| AU7446600A (en) | Novel diarylamide derivatives and use thereof as medicines | |
| HRP20131174T1 (hr) | Derivati pirazola, upotrijebljeni kao antagonisti receptora ccr4 | |
| US20040198780A1 (en) | Inhibitors of cathepsin S | |
| HRP20130989T1 (hr) | (2r) -2-[(4-sulfonil)aminofenil] propanamidi i farmaceutski sastavi koji ih sadrže | |
| JP2007261945A (ja) | チアゾール誘導体 | |
| EP1470102A1 (en) | Substituted methylene amide derivatives as modulators of protein tyrosine phosphatases (ptps) | |
| AU2003239296A1 (en) | Substituted methylene amide derivatives as Modulators of Protein Tyrosine Phosphatases (PTPs) | |
| ES2221470T3 (es) | Inhibidores de virus herpes derivados de alfa-metilbencil-tiourea que contienen un grupo fenilenodiamina. | |
| RU2002127729A (ru) | Новые гетероциклические и бензольные производные липоевой кислоты, их получение и применение в качестве лекарственных средств | |
| JPH02160761A (ja) | スルホンアミド及びこれを含有する心臓―及び循環疾患、腎臓機能障害、喘息、血栓症及び脳虚血性状態の治療用薬剤 | |
| US7384970B2 (en) | Inhibitors of cathepsin S |